Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders

Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis

(2018) Ivan Jelcic et al.   CELL

Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial

(2017) Zahra Nikoo et al.   JOURNAL OF NEUROLOGY

Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy

(2017) Aiden Haghikia et al.   LANCET NEUROLOGY

Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry

(2017) Tim Spelman et al.   Multiple Sclerosis Journal

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry

(2017) Tim Spelman et al.   Multiple Sclerosis Journal

Rituximab in multiple sclerosis

(2016) Jonatan Salzer et al.   NEUROLOGY

Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients

(2014) Arumugam Palanichamy et al.   JOURNAL OF IMMUNOLOGY

Therapies for multiple sclerosis: translational achievements and outstanding needs

(2013) Aiden Haghikia et al.   TRENDS IN MOLECULAR MEDICINE

Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?

(2009) Amit Bar-Or et al.   ANNALS OF NEUROLOGY

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

(2008) Amit Bar-Or et al.   ANNALS OF NEUROLOGY

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE